NCT01254864 2025-01-27
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
M.D. Anderson Cancer Center
Phase 2 Completed
Clinical Trials
8 trialsNCT00599313 2018-10-25
Phase II Sunitinib Prog Met AIPC
US Oncology Research
Phase 2 Completed
NCT00879619 2017-02-01
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
University of California, Irvine
Phase 1/2 Terminated
NCT00734851 2015-12-23
Multimodality Phase II Study in Prostate Cancer
Duke University
Phase 2 Terminated
NCT00672594 2014-08-04
Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy
Duke University
Phase 2 Completed
NCT00676650 2013-03-08
SUN 1120
Pfizer
Phase 3 Terminated
NCT00299741 2012-12-19
Study of SU11248 in Men With Advanced Prostate Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00137436 2011-08-29
Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Prostate Cancer
Pfizer
Phase 1/2 Completed